2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          We aimed to elucidate the place of dynamic O-(2-[ 18F]-fluoroethyl)-L-tyrosine ( 18F-FET) PET in prognostic models of gadolinium (Gd)-negative gliomas.

          Methods

          In 98 patients with Gd-negative gliomas undergoing 18F-FET PET guided biopsy, time activity curves (TACs) of each tumor were qualitatively categorized as either increasing or decreasing. Additionally, post-hoc quantitative analyses were done using minimal time-to-peak (TTP min) measurements. Prognostic factors were obtained from multivariate hazards models. The fit of the biospecimen- and imaging-derived models was compared.

          Results

          A homogeneous increasing, mixed, and homogeneous decreasing TAC pattern was seen in 51, 19, and 28 tumors, respectively. Mixed TAC tumors exhibited both increasing and decreasing TACs. Corresponding adjusted 5-year survival was 85%, 47%, and 19%, respectively ( P < 0.001). Qualitative and quantitative TAC measurements were highly intercorrelated ( P < 0.0001). TTP min was longest (shortest) in the homogeneous increasing (decreasing) TAC group and in between in the mixed TAC group. TTP min was longer in isocitrate dehydrogenase ( IDH)-mutant tumors ( P < 0.001). Outcome was similarly precisely predicted by biospecimen- and imaging-derived models. In the biospecimen model, World Health Organization (WHO) grade ( P < 0.0001) and IDH status ( P < 0.001) were predictors for survival. Outcome of homogeneous increasing (homogeneous decreasing) TAC tumors was nearly identical, with both TTP min > 25 min (TTP min ≤ 12.5 min) tumors and IDH-mutant grade II ( IDH-wildtype) gliomas. Outcome of mixed TAC tumors matched that of both intermediate TTP min (>12.5 min and ≤25 min) and IDH-mutant, grade III gliomas. Each of the 3 prognostic clusters differed significantly from the other ones of the respective models ( P < 0.001).

          Conclusion

          TAC measurements constitute a powerful biomarker independent from tumor grade and IDH status.

          Related collections

          Author and article information

          Journal
          Neuro Oncol
          Neuro-oncology
          neuonc
          Neuro-Oncology
          Oxford University Press (US )
          1522-8517
          1523-5866
          February 2019
          09 June 2018
          14 February 2020
          : 21
          : 2
          : 274-284
          Affiliations
          [1 ]Department of Neurosurgery, University of Munich, Munich, Germany
          [2 ]Department of Nuclear Medicine, University of Munich, Munich, Germany
          [3 ]Center for Neuropathology, University of Munich, Munich, Germany
          [4 ]Department of Clinical Radiology, University of Munich, Munich, Germany
          [5 ]Department of Anaesthesiology, University of Munich, Munich, Germany
          [6 ]German Cancer Consortium, partner site Munich, Germany
          [7 ]Division of Nuclear Medicine and Clinical Molecular Imaging, Department of Radiology, University of Tübingen, Tübingen, Germany
          [8 ]Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
          [9 ]Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
          [10 ]Research Institute Children’s Cancer Center Hamburg, Hamburg, Germany
          Author notes
          Corresponding Author: Friedrich-Wilhelm Kreth, MD, Department of Neurosurgery, University of Munich—Campus Grosshadern, Germany ( Friedrich-Wilhelm.Kreth@ 123456med.uni-muenchen.de ).
          Article
          PMC6374762 PMC6374762 6374762 noy098
          10.1093/neuonc/noy098
          6374762
          29893965
          005fc4a0-0d5c-4b95-b67c-24db33de7661
          © The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

          This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model ( https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

          History
          Page count
          Pages: 11
          Funding
          Funded by: German Cancer Aid (Deutsche Krebshilfe)
          Award ID: 70-3163-Wi 3
          Categories
          Neuroimaging

          biomarkers,targeted therapy,glioma, 18F-FET PET,prognosis
          biomarkers, targeted therapy, glioma, 18F-FET PET, prognosis

          Comments

          Comment on this article